In systemic pharmacological treatment, sorafenib (inhibitor of VEGFR1, VEGFR2 and VEGFR3) is the first-line systemic treatment of patients with advanced-stage HCC, and results of phase III randomized controlled trials have proved that the function of sorafenib in prolonging the survival of advanced-stage HCC patients [4, 13]. The gene discussed is KDR; the disease is hepatocellular carcinoma.